Prime immunization with rotavirus VLP 2/6 followed by boosting with an adenovirus expressing VP6 induces protective immunization against rotavirus in mice

Virology Journal

Volumn 8, Issue , 2011, Pages

  Zhou, Hongli ^a,b   Guo, Li ^a,b   Wang, Min ^a   Qu, Jianguo ^a   Zhao, Zhendong ^b   Wang, Jianwei ^b   Hung, Tao ^a,b  

^a CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^b PEKING UNION MEDICAL COLLEGE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G; PROTEIN VP6; ROTAVIRUS VACCINE; CAPSID PROTEIN; RECOMBINANT VACCINE; VIRUS ANTIGEN; VIRUS VACCINE; VP2 PROTEIN, ROTAVIRUS; VP6 PROTEIN, ROTAVIRUS;

ADOLESCENT; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; FEMALE; GASTROENTERITIS; HUMORAL IMMUNITY; IMMUNIZATION; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; ROTAVIRUS; VIRUS LIKE AGENT; VIRUS RECOMBINANT; VIRUS SHEDDING; ADENOVIRUS; ANIMAL; BAGG ALBINO MOUSE; FECES; GENETICS; IMMUNOLOGY; RANDOMIZATION; ROTAVIRUS INFECTION; VIROLOGY;

ADENOVIRIDAE; MUS; ROTAVIRUS;

ADENOVIRIDAE; ANIMALS; ANTIGENS, VIRAL; CAPSID PROTEINS; FECES; FEMALE; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; IMMUNITY, MUCOSAL; IMMUNIZATION, SECONDARY; MICE; MICE, INBRED BALB C; RANDOM ALLOCATION; ROTAVIRUS; ROTAVIRUS INFECTIONS; VACCINES, SYNTHETIC; VIRAL VACCINES;

EID: 78650776870     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-8-3     Document Type: Article

References (51)

1. Rotavirus and severe childhood diarrhea. UD Parashar CJ Gibson JS Bresee RI Glass, Emerg Infect Dis 2006 12 304 306 16494759
2. Global illness and deaths caused by rotavirus disease in children. UD Parashar EG Hummelman JS Bresee MA Miller RI Glass, Emerg Infect Dis 2003 9 565 572 12737740
3. Withdrawal of rotavirus vaccine recommendations. MMWR 1999 48 1007 10577495
4. The promise of new rotavirus vaccines. RI Glass UD Parashar, N Engl J Med 2006 354 75 77 10.1056/NEJMe058285 16394305
5. Rotarix: a rotavirus vaccine for the world. R Ward D Bernstein, Clin Infect Dis 2009 48 222 228 10.1086/595702 19072246
6. Prevention of rotavirus gastroenteritis among infants and children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). U D. JP Alexander RI Glass, MMWR Recomm Rep 2006 55 1 13
7. Influence of potential protective mechanisms on the development of live rotavirus vaccines. RL Ward HF Clark PA Offit, J Infect Dis 2010 202 72 s79 10.1086/653549 20684721
8. The VP6 protein of rotavirus interacts with a large fraction of human naive B cells via surface immunoglobulins. N Parez A Garbarg-Chenon C Fourgeux FL Deist A Servant-Delmas A Charpilienne J Cohen I Schwartz-Cornil, J Virol 2004 78 12489 12496 10.1128/JVI.78.22.12489-12496.2004 15507636
9. Functional mapping of protective domains and epitopes in the rotavirus VP6 protein. AHC Choi M Basu MM Mcneal J Flint JL Vancott JD Clements RL Ward, J Virol 2000 74 11574 11580 10.1128/JVI.74.24.11574-11580.2000 11090155
10. CD4 T cells are the only lymphocytes needed to protect mice against rotavirus shedding after intranasal immunization with a chimeric VP6 protein and the adjuvant LT(R192G). MM McNeal JL VanCott AHC Choi M Basu JA Flint SC Stone JD Clements RL Ward, J Virol 2002 76 560 568 10.1128/JVI.76.2.560-568.2002 11752147
11. Nasal immunization of mice with a rotavirus DNA vaccine that induces protective intestinal IgA antibodies. A García-Díaz P Lápez-Andjar JR Díaz R Montava CT Barcelá JM Ribes J Buesa, Vaccine 2004 23 489 498 15530697
12. Mucosal and systemic antibody responses and protection induced by a prime/boost rotavirus-DNA vaccine in a gnotobiotic pig model. L Yuan MS Azevedo AM Gonzalez KI Jeong T Van Nguyen P Lewis C Iosef JE Herrmann LJ Saif, Vaccine 2005 23 3925 3936 10.1016/j.vaccine.2005.03.009 15917114
13. Magnitude of serum and intestinal antibody responses induced by sequential replicating and nonreplicating rotavirus vaccines in gnotobiotic pigs and correlation with protection. MS Azevedo L Yuan C Iosef KO Chang Y Kim TV Nguyen LJ Saif, Clin Diagn Lab Immun 2004 11 12 20
14. VP6: a candidate rotavirus vaccine. RL Ward MM Monica, J Infect Dis 2010 202 101 s107 10.1086/653556 20684688
15. Characterization of virus-Like particles produced by the expression of rotavirus capsid proteins in insect cells. SE Crawford M Labbe J Cohen MH Burroughs Y-J Zhou MK Estes, J Virol 1994 68 5945 5952 8057471
16. Rotavirus 2/6 virus-like particles administered intranasally in mice, with or without the mucosal adjuvants cholera toxin and Escherichia coli heat-labile toxin, induce a Th1/Th2-like immune pesponse. C Fromantin B Jamot J Cohen L Piroth, J Virol 2001 75 11010 11016 10.1128/JVI.75.22.11010-11016.2001 11602741
17. Antibody responses to human rotavirus (HRV) in gnotobiotic pigs following a new prime/boost vaccine strategy using oral attenuated HRV priming and intranasal VP2/6 rotavirus-like particle (VLP) boosting with ISCOM. AM Gonzalez TV Nguyen MS Azevedo K Jeong, Clin Exp Immunol 2004 135 361 372 10.1111/j.1365-2249.2004.02395.x 15008967
18. Nasal immunization of mice with virus-like particles protects offspring against rotavirus diarrhea. A Coste JC Sirard K Johansen J Cohen JP Kraehenbuhl, J Virol 2000 74 8966 8971 10.1128/JVI.74.19.8966-8971.2000 10982340
19. Oral and intraperitoneal immunization with rotavirus 2/6 virus-like particles stimulates a systemic and mucosal immune response in mice. G Shuttleworth D Eckery P Awram, Arch Virol 2005 150 341 349 10.1007/s00705-004- 0447-z 15578236
20. Oral immunization of rhesus macaques with adenoviral HIV vaccines using enteric-coated capsules. GT Mercier PN Nehete MF Passeri BN Nehete EA Weaver NS Templeton K Schluns SS Buchl KJ Sastry MA Barry, Vaccine 2007 25 8687 8701 18063450
21. Partial protection against H5N1 influenza in mice with a single dose of a chimpanzee adenovirus vector expressing nucleoprotein. S Roy GP Kobinger J Lin J Figueredo R Calcedo D Kobasa JM Wilson, Vaccine 2007 25 6845 6851 10.1016/j.vaccine.2007.07.035 17728024
22. Severe acute respiratory syndrome vaccine efficacy in ferrets: whole killed virus and adenovirus-vectored vaccines. RH See M Petric DJ Lawrence CP Mok T Rowe LA Zitzow KP Karunakaran TG Voss RC Brunham J Gauldie, et al. J Gen Virol 2008 89 2136 2146 10.1099/vir.0.2008/001891-0 18753223
23. Enhanced protection against Ebola virus mediated by an improved adenovirus-based vaccine. JS Richardson MK Yao KN Tran MA Croyle JE Strong H Feldmann GP Kobinger, PLoS One 2009 4 5308 10.1371/journal.pone.0005308 19390586
24. Mucosal delivery of adenovirus-based vaccine protects against Ebola virus infection in mice. A Patel Y Zhang M Croyle K Tran M Gray J Strong H Feldmann JM Wilson GP Kobinger, J Infect Dis 2007 196 413 420 10.1086/520603 17940978
25. Expression of the main structural antigen VP6 of human rotavirus by recombinant adenovirus and immune responses induced in vivo. J He J Wang X Jiang D Wang L Wen J Dong J Qu T Hong, Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 2002 16 109 113 12196818
26. Robust HIV-specific immune responses were induced by DNA vaccine prime followed by attenuated recombinant vaccinia virus (LC16m8 strain) boost. K Shinoda K-Q Xin Y Kojima S Saha K Okuda K Okuda, Clin Immunol 2006 119 32 37 10.1016/j.clim.2005.12.007 16458074
27. DNA prime/protein boost immunization against HIV clade C: safety and immunogenicity in mice. RA Rasmussen H Ong C Kittel CR Ruprecht F Ferrantelli S-L Hu P Policano J McKenna J Moon B Travis RM Ruprecht, Vaccine 2006 24 2324 2332 10.1016/j.vaccine.2005.11.063 16406147
28. Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers. I Cebere L Dorrell H McShane A Simmons S McCormack C Schmidt C Smith M Brooks JE Roberts SC Darwin, et al. Vaccine 2006 24 417 425 10.1016/j.vaccine.2005.08.041 16176847
29. A recombinant adenovirus prime-virus-like particle boost regimen elicits effective and specific immunities against norovirus in mice. L Guo H Zhou M Wang J Song B Han Y Shu L Ren H Si J Qu Z Zhao, et al. Vaccine 2009 27 5233 5238 10.1016/j.vaccine.2009.06.065 19589399
30. Rotavirus virus-like particles administered mucosally induce protective immunity. CM O'Neal SE Crawford MK Estes ME Conner, J Virol 1997 71 8707 8717 9343229
31. Immunogenicity and protective efficacy of rotavirus 2/6-virus-like particles produced by a dual baculovirus expression vector and administered intramuscularly, intranasally, or orally to mice. A Bertolotti-Ciarlet M Ciarlet SE Crawford ME Conner MK Estes, Vaccine 2003 21 3885 3990 10.1016/S0264- 410X(03)00308-6 12922123
32. Enhanced mucosal immunoglobulin A response of intranasal adenoviral vector human immunodeficiency virus vaccine and localization in the central nervous system. F Lemiale W-p Kong LM Akyürek X Ling Y Huang BK Chakrabarti M Eckhaus GJ Nabel, J Virol 2003 77 10078 10087 10.1128/JVI.77.18.10078-10087. 2003 12941918
33. Immunogenicity of an E1-deleted recombinant human adenovirus against rabies by different routes of administration. A Vos A Neubert E Pommerening T Müller L Döhner L Neubert K Hughes, J Gen Virol 2001 82 2191 2197 11514729
34. Intramuscular rather than oral administration of replication-defective adenoviral vaccine vector induces specific CD8+ T cell responses in the gut. SW Lin AS Cun K Harris-McCoy HC Ertl, Vaccine 2007 25 2187 2193 10.1016/j.vaccine.2006.11.044 17229501
35. Innate signaling regulates cross-priming at the level of DC licensing and not antigen presentation. SA Keller K Schwarz V Manolova CE von Allmen MG Kinzler M Bauer S Muntwiler P Saudan MF Bachmann, Eur J Immunol 2010 40 103 112 10.1002/eji.200939559 19877013
36. Progress and prospects: immune responses to viral vectors. S Nayak RW Herzog, Gene Ther 2010 17 295 304 10.1038/gt.2009.148 19907498
37. Immunologic basis of vaccine vectors. MA Liu, Immunity 2010 33 504 515 10.1016/j.immuni.2010.10.004 21029961
38. Systems vaccinology. B Pulendran S Li HI Nakaya, Immunity 2010 33 516 529 10.1016/j.immuni.2010.10.006 21029962
39. Subunit rotavirus vaccine administered parenterally to rabbits induces active protective immunity. M Ciarlet SE Crawford C Barone A Bertolotti-Ciarlet RF Ramig MK Estes ME Conner, J Virol 1998 72 9233 9246 9765471
40. Antibody-secreting cell responses to rotavirus proteins in gnotobiotic pigs inoculated with attenuated or virulent human rotavirus. KO Chang OH Vandal L Yuan DC Hodgins LJ Saif, J Clin Microbiol 2001 39 2807 2813 10.1128/JCM.39.8.2807-2813.2001 11473996
41. Protective immunity and antibody-secreting cell responses eicited by combined oral attenuated Wa human rotavirus and intranasal Wa 2/6-VLPs with mutant Escherichia coli heat-labile toxin in gnotobiotic pigs. L Yuan C Iosef MSP Azevedo Y Kim Y Qian A Geyer TV Nguyen K-O Chang LJ Saif, J Virol 2001 75 9229 9238 10.1128/JVI.75.19.9229-9238.2001 11533185
42. Immunity and correlates of protection for rotavirus vaccines. MA Franco J Angel HB Greenberg, Vaccine 2006 24 2718 2731 10.1016/j.vaccine.2005.12.048 16446014
43. Efficient intranasal immunization of newborn mice with recombinant adenovirus expressing rotavirus protein VP4 against oral rotavirus infection. X Liu T Yang Q Sun M Sun, Acta Virol 2005 49 17 22 15929394
44. Serum IgA levels induced by rotavirus natural infection, but not following immunization with the RRV-TV vaccine (Rotashield), correlate with protection. R Gonzalez M Franco L Sarmiento M Romero IP Schael, J Med Virol 2005 76 608 612 10.1002/jmv.20404 15977224
45. Characterization of homologous and heterologous rotavirus-specific T-cell responses in infant and adult mice. MC Jaimes N Feng HB Greenberg, J Virol 2005 79 4568 4579 10.1128/JVI.79.8.4568-4579.2005 15795243
46. Possible mechanisms of protection elicited by candidate rotavirus vaccines as determined with the adult mouse model. RL Ward, Viral Immunol 2003 16 17 24 10.1089/088282403763635410 12725685
47. Interaction of rotavirus with human myeloid dendritic cells. CF Narvez J Angel MA Franco, J Virol 2005 79 14526 14535 16282452
48. Rotavirus vaccines: how they work or don't work. RL Ward, Expert Rev Mol Med 2008 10 5 10.1017/S1462399408000574 18267049
49. Intranasal administration of a recombinant adenovirus expressing the norovirus capsid protein stimulates specific humoral, mucosal, and cellular immune responses in mice. L Guo J Wang H Zhou H Si M Wang J Song, Vaccine 2008 26 460 468 10.1016/j.vaccine.2007.11.039 18160189
50. Codon optimization and expression of norovirus capsid proteins in insect cells. L Guo H Zhou J Qu J Wang X Xu T Hung, Virologica Sinica 2006 21 121 125
51. Identification of a T-helper cell epitope on the rotavirus VP6 protein. DM Bãos S Lopez CF Arias FR Esquivel, J Virol 1997 71 419 426 8985366